ZYBERNO
Stock Report
Updated Aug 30, 2026

Relay Therapeutics, Inc. (RLAY)

Healthcare • NASDAQ

$18.77

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
39.0/100
WEAK BUSINESS
Relay Therapeutics, Inc. (RLAY) scores 39/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-42.3%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.06x)
Operating Margin (Operational Efficiency):CRITICAL (-2,999.7%)
Return on Capital (Capital Efficiency):CRITICAL (-29.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Relay Therapeutics, Inc. (RLAY) stock report — Zyberno Score 39/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RLAY generated -$235.87M in Owner Earnings. Capital was deployed as follows: $410.00K invested in capital expenditures. Reinvestment rate: 1.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:18.77
Market Cap:$3.81B

Valuation Multiples (3)

P/B Ratio:4.28x
P/S Ratio:367.91x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.72B

Price Action & Momentum (3)

Momentum Percentile:99 / 100
% of 52-Week High:88.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-38.7%
Reinvestment Rate:1.4%
Fundamental Growth Rate (g):-0.4%

Margin Analysis (3)

Operating Margin Ttm:-2,999.7%
Net Margin Ttm:-2,763.9%
Ebitda Margin:-2,972.1%

TTM Performance (2)

Operating Margin Ttm:-2,999.7%
Net Margin Ttm:-2,763.9%

Yield Metrics (2)

Earnings Yield:-$8.31
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-247.1%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):63.4%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:18.27x
Quick Ratio:18.27x
Cash Ratio:2.39x

Leverage Analysis (3)

Debt To Equity Ttm:0.06x
Debt-to-Equity Ratio:0.06x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:877,278,000.00
Cash And Cash Equivalents:121,189,000.00
Long Term Debt:$26.64M
Net Debt:-$90.53M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $10.35M
Linear Growth: 63.4%
📊 Click to view full RLAY Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$310.44M

Bottom Line Performance (3)

-$286.04M
Income Before Tax:$0.00
Ebitda Ttm:-307,583,000.00

Operating Expenses (5)

Operating Expenses:320,785,000.00
R And D Expense:270,723,000.00
Sga Expense:50,062,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:77,349.4%
Sga To Revenue Percentage:14,303.4%
Ebitda Margin:-2,972.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$967.46M
Current Assets:$928.08M
Ppe Net:862,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:77,448,000.00
Current Liabilities:50,804,000.00
Long Term Debt:$26.64M
Short Term Debt:$4.01M

Equity & Capital (3)

Equity:$890.01M
Retained Earnings:-$2.17B
Common Stock:450,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:11,459,000.00

Special Items (2)

Contract Liabilities:7,679,000.00
Stock Based Compensation:10,537,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$213.36M-$213.77M

Investment Activities (2)

Investing Cash Flow:$32.90M
Capital Expenditures Ttm:410,000.00

Financing Activities (3)

Financing Cash Flow:$138.78M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,853,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.56
-$1.56
Earnings Per Share Ttm:-$1.41

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.05
Operating Cash Flow Per Share:-$1.16

Book Value & Capital (2)

Book Value Per Share:$4.39
Cash Per Share:0.60

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.01x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:404.15
Cash Conversion Cycle:-2,402.15
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$235.87M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.4%
Fundamental Growth Rate (g):-0.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):63.4%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-6.4%
C. Company Profile & Context

Corporate Information (6)

Symbol:RLAY
Company Name:Relay Therapeutics, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:202.85M
Shares Outstanding Basic:202.85M
Shares Outstanding Diluted:110.91M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 20:06:31 UTC
Data Timestamp:2026-08-30T20:06:31.367127
Scroll to Top